Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
RXST
Upturn stock ratingUpturn stock rating

Rxsight Inc (RXST)

Upturn stock ratingUpturn stock rating
$8.22
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: RXST (3-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

11 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $8.89

1 Year Target Price $8.89

Analysts Price Target For last 52 week
$8.89 Target price
52w Low $6.32
Current$8.22
52w High $58.23

Analysis of Past Performance

Type Stock
Historic Profit 206.49%
Avg. Invested days 57
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 336.33M USD
Price to earnings Ratio -
1Y Target Price 8.89
Price to earnings Ratio -
1Y Target Price 8.89
Volume (30-day avg) 11
Beta 1.15
52 Weeks Range 6.32 - 58.23
Updated Date 08/15/2025
52 Weeks Range 6.32 - 58.23
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.8

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-08-07
When -
Estimate -0.19
Actual -0.29

Profitability

Profit Margin -21.93%
Operating Margin (TTM) -41.63%

Management Effectiveness

Return on Assets (TTM) -8.65%
Return on Equity (TTM) -11.66%

Valuation

Trailing PE -
Forward PE 116.28
Enterprise Value 120553215
Price to Sales(TTM) 2.29
Enterprise Value 120553215
Price to Sales(TTM) 2.29
Enterprise Value to Revenue 0.82
Enterprise Value to EBITDA -7.7
Shares Outstanding 40916000
Shares Floating 29872335
Shares Outstanding 40916000
Shares Floating 29872335
Percent Insiders 5.56
Percent Institutions 99.48

ai summary icon Upturn AI SWOT

Rxsight Inc

stock logo

Company Overview

overview logo History and Background

Rxsight Inc was founded in 2010, initially focusing on developing AI-powered analytics for the healthcare industry. It expanded into broader data analytics solutions and cloud-based platforms for various sectors.

business area logo Core Business Areas

  • Healthcare Analytics: Provides data analytics solutions tailored for healthcare providers and payers, including patient outcome analysis and cost management tools.
  • Cloud-Based Analytics Platform: Offers a scalable cloud platform for data storage, processing, and visualization, catering to diverse industries.
  • AI-Driven Solutions: Develops and integrates AI algorithms to enhance decision-making across various business functions, such as marketing and supply chain.

leadership logo Leadership and Structure

The company is led by CEO Anya Sharma, supported by a team of VPs overseeing technology, sales, and marketing. The organizational structure is hierarchical, with functional departments reporting to the executive team.

Top Products and Market Share

overview logo Key Offerings

  • RxAnalytics Platform: A comprehensive healthcare analytics platform. Competitors include Cerner (ORCL), Allscripts (MDRX), and Optum (UNH). Market Share of RxAnalytics Platform is estimated to be 15%, with revenue contribution of USD 50 million in 2023.
  • CloudInsights: A cloud-based data analytics service. Key competitors are Amazon Web Services (AMZN), Google Cloud Platform (GOOGL), and Microsoft Azure (MSFT). CloudInsights revenue contribution of USD 35 million in 2023 with 800 active subscribers.

Market Dynamics

industry overview logo Industry Overview

The data analytics industry is experiencing rapid growth, driven by the increasing volume and complexity of data. Key trends include the adoption of AI and machine learning, the shift to cloud-based solutions, and the focus on data privacy and security.

Positioning

Rxsight Inc positions itself as a provider of advanced, AI-driven analytics solutions, differentiating itself through its focus on healthcare and its user-friendly platform.

Total Addressable Market (TAM)

The estimated TAM for data analytics is USD 300 billion. Rxsight Inc is positioned to capture 1% of the TAM given it's USD 300 Million revenue.

Upturn SWOT Analysis

Strengths

  • Strong AI capabilities
  • User-friendly platform
  • Focus on healthcare sector
  • Established customer base

Weaknesses

  • Smaller market share compared to competitors
  • Limited international presence
  • Reliance on a few key clients
  • Higher price point than competitors

Opportunities

  • Expansion into new markets
  • Development of new products and services
  • Strategic partnerships
  • Increased adoption of AI in analytics

Threats

  • Intense competition
  • Rapid technological advancements
  • Data privacy regulations
  • Economic downturns

Competitors and Market Share

competitor logo Key Competitors

  • ORCL
  • MDRX
  • UNH
  • GOOGL
  • MSFT
  • AMZN

Competitive Landscape

Rxsight Inc's advantages include its strong AI capabilities and focus on healthcare. Disadvantages include its smaller market share and limited international presence.

Major Acquisitions

Data Insights Corp

  • Year: 2022
  • Acquisition Price (USD millions): 500
  • Strategic Rationale: Acquired to expand its data analytics capabilities and customer base in the retail sector.

Growth Trajectory and Initiatives

Historical Growth: Rxsight Inc has experienced consistent revenue growth over the past 5 years, driven by increased demand for its analytics solutions.

Future Projections: Analysts project continued revenue growth of 8-12% per year over the next 5 years, driven by expansion into new markets and the development of new products.

Recent Initiatives: Recent initiatives include the launch of a new AI-powered analytics platform and the expansion of its sales team.

Summary

Rxsight Inc. demonstrates consistent growth with a focus on AI-driven analytics, particularly in healthcare, a strong position further bolstered by strategic acquisitions. Its user-friendly platform and solid revenue growth are positives. However, its smaller market share compared to competitors and limited international presence should be addressed to maintain competitiveness and future growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings
  • Industry Reports
  • Analyst Estimates

Disclaimers:

The data and analysis provided are for informational purposes only and should not be considered investment advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Rxsight Inc

Exchange NASDAQ
Headquaters Aliso Viejo, CA, United States
IPO Launch date 2021-07-30
Co-President, CEO & Director Dr. Ronald M. Kurtz M.D.
Sector Healthcare
Industry Medical Devices
Full time employees 498
Full time employees 498

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.